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There is a persistent need for new antimalarials due to the evolution of drug-resistant parasites. Under the auspices of the Medicines for Malaria Venture (MMV), new drug candidates that are active against artemisinin-resistant isolates of Plasmodium falciparum are being developed; the frontrunners are artefenomel, KAF156, cipargamin, DSM265, MMV390048, ferroquine, and tafenoquine ([@B1], [@B2]). However, the choice of the right partner drug will be critical for the success of these new molecules, as the WHO enforces the application of antimalarials in combination therapy ([@B3]). In addition to protecting each other from drug resistance, two molecules to be combined need to be compatible for coformulation, should have matching pharmacokinetic profiles, and must not have unfavorable polypharmacology ([@B4][@B5][@B6]). Ideally, the two molecules would potentiate each other, thereby decreasing the duration of treatment and the required doses. Thus, combinatorial chemotherapy not only can reduce the risk of drug resistance but also can enhance drug safety and drug efficacy, enabling the ambitious goal of a "single-exposure radical cure" ([@B7], [@B8]).

Here we propose to support the matchmaking of antimalarial candidates by learning from yeast reverse genetics. Saccharomyces cerevisiae is probably the best studied of all eukaryotes. Only about 20% of its protein-coding genes are essential for growth on rich medium ([@B9]). High-throughput crossing experiments have shown that many viable S. cerevisiae gene deletion mutants possess synthetic phenotypes, i.e., growth defects that become apparent only in the absence of another nonessential gene. The concept of genetic synthetic lethality can be adopted to combination chemotherapy ([@B8], [@B10][@B11][@B12]). The principal idea is to extrapolate from synthetic lethal gene pairs in S. cerevisiae to orthologous pairs of genes in P. falciparum, assuming that the combined inhibition of the respective gene products will produce a synergistic effect. However, this seemingly straightforward approach is complicated by the fact that S. cerevisiae is more closely related to Homo sapiens than to P. falciparum ([@B13]). Thus, a drug combination inferred from yeast synthetic genetic lethality might enhance the toxicity to humans rather than enhancing the antimalarial efficacy. To avoid such a scenario, we developed an algorithm to exclude gene pairs that are conserved in H. sapiens.

Yeast synthetic lethal gene pairs were obtained from BioGRID 3.4 ([@B14]) and pairs and groups of orthologous genes from the OrthoMCL 5 database, based on the similarity of the derived protein sequences ([@B15], [@B16]). Mining the OrthoMCL database with the 16,217 synthetic lethal gene pairs of S. cerevisiae identified in BioGRID, we found that only 1,505 pairs (9.3%) had direct orthologues in P. falciparum for both gene products ([Fig. 1](#F1){ref-type="fig"}). From this set, we tested all of the proteins for the presence of an orthologue in the human proteome, again referring to the downloaded OrthoMCL database. This assessment included direct pairwise orthology between the P. falciparum or S. cerevisiae protein and a H. sapiens protein or indirect orthology in which either the malaria protein or its yeast orthologue belonged to an OrthoMCL group that also contained a human protein ([Fig. 1](#F1){ref-type="fig"}). All of the P. falciparum gene pairs for which both gene products tested positive for direct or indirect human orthology were eliminated. This process yielded 37 pairs composed of 55 unique P. falciparum proteins that fulfilled the conditions that (i) their direct orthologues in S. cerevisiae exhibit synthetic lethality and (ii) at least one of the two proteins has neither a direct nor an indirect orthologue in the human proteome. Therefore, we suggest these pairs as targets for combinatorial chemotherapy. The comparative genomics pipeline ([Fig. 1](#F1){ref-type="fig"}) is built with self-developed Python scripts that are available for download at the GitHub repository (<https://github.com/suvi-subra/SynthLeth>).

![Graphic representation of the algorithm, with the numbers of P. falciparum gene pairs that passed the filters; the final 37 are shown in [Table 1](#T1){ref-type="table"}. Yellow, S. cerevisiae; blue, P. falciparum; red, H. sapiens.](zac0041870030001){#F1}

The final set of 37 pairs was enriched in druggable proteins ([Table 1](#T1){ref-type="table"}). Of the 55 proteins in the set, 30 either had been validated as drug targets or had a positive "druggability index," as predicted by TDR Targets ([@B17]). Some of the suggested combinations affected the same pathway, e.g., the pyridoxal kinase-like protein and pyridoxine biosynthesis protein involved in vitamin B~6~ metabolism or NAD(P)H-dependent glutamate synthase and NADP-specific glutamate dehydrogenase; the latter is selectively inhibited by isophthalic acid ([@B18]), while glutamate synthase had been suggested as a target based on comparative genomics ([@B19]). Calcineurin subunit B paired with the P. falciparum cation/H^+^ antiporter (PfCHA), which is sensitive to known inhibitors such as KB-R7943 ([@B20]). Hubs of inferred interactions were P. falciparum apurinic/apyrimidinic endonuclease 1 (PfAPN1) and the P. falciparum U5 small nuclear ribonucleoprotein (PfSNU114) of the spliceosome, both of which are involved in the processing of nucleic acids. Two proteins in the target set were of particular pharmacological interest, namely, P. falciparum Ca^2+^-ATPase 4 (PfATP4) and P. falciparum phosphatidylinositol 4-kinase (PfPI4K). Either protein is targeted by new antimalarial candidates ([@B21][@B22][@B27]). PfATP4 is the target of cipargamin and paired with PfCHA ([Table 1](#T1){ref-type="table"}), suggesting testing for potential synergy between cipargamin and KB-R7943. PfPI4K, the target of imidazolopiperazines and MMV390048, paired with ubiquitin-conjugating enzyme E2 ([Table 1](#T1){ref-type="table"}). An inhibitor of Atg8-Atg3 interactions was identified from the MMV Malaria Box ([@B28]), and ubiquitin-protein ligase E3 was proposed as an antimalarial target ([@B29]). The inferred link between phosphatidylinositol 4-kinase and ubiquitination suggests testing for potential synergy between PfPI4K inhibitors and P. falciparum proteasome inhibitors ([@B30][@B31][@B32]).

###### 

Pairs of P. falciparum proteins suggested as targets for combinatorial chemotherapy, based on synthetic lethal genetic interactions in S. cerevisiae

  Gene 1 identification   Gene 1 product[^*a*^](#T1F1){ref-type="table-fn"}                   Gene 2 identification   Gene 2 product
  ----------------------- ------------------------------------------------------------------- ----------------------- -------------------------------------------------
  PF14_0492               Calcineurin subunit B                                               PFF0170w                Cation/H+ antiporter
  PFL0590c                Non-SERCA-type Ca^2+^-transporting P-ATPase 4                       PFF0170w                Cation/H+ antiporter
  PFE0485w                Phosphatidylinositol 4-kinase                                       PFF0305c                Ubiquitin-conjugating enzyme E2
  PF08_0031               Dicarboxylate/tricarboxylate carrier                                mal_mito_2              Cytochrome *c* oxidase subunit 1
  PFF1105c                Chorismate synthase                                                 PF14_0511               Glucose-6-phosphate dehydrogenase
  PFL2465c                Thymidylate kinase                                                  PF13_0176               Apurinic/apyrimidinic endonuclease
  MAL13P1.346             DNA repair endonuclease                                             PF13_0176               Apurinic/apyrimidinic endonuclease
  PFB0160w                ERCC1 nucleotide excision repair protein                            PF13_0176               Apurinic/apyrimidinic endonuclease
  PFF0715c                Endonuclease III homologue                                          PF13_0176               Apurinic/apyrimidinic endonuclease
  PFD0865c                Cdc2-related protein kinase 1                                       PFF0165c                Conserved Plasmodium protein, unknown function
  PFL1635w                Sentrin-specific protease 1                                         PF10_0092               Metallopeptidase
  PF13_0251               DNA topoisomerase 3                                                 PF10_0092               Metallopeptidase
  PFF0775w                Pyridoxal kinase-like protein                                       PFF1025c                Pyridoxine biosynthesis protein
  PF11_0192               Histone acetyltransferase                                           PFF1180w                Anaphase-promoting complex subunit
  PFL2440w                DNA repair protein                                                  MAL7P1.94               Prefoldin subunit 3
  PF11_0087               DNA repair protein                                                  PF10_0041               U5 small nuclear ribonucleoprotein
  PFB0445c                ATP-dependent RNA helicase                                          PF10_0041               U5 small nuclear ribonucleoprotein
  PFE0925c                ATP-dependent RNA helicase                                          PF10_0041               U5 small nuclear ribonucleoprotein
  PF10_0294               Pre-mRNA-splicing factor ATP-dependent RNA helicase                 PF10_0041               U5 small nuclear ribonucleoprotein
  PFC1060c                U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated protein 1   PF10_0041               U5 small nuclear ribonucleoprotein
  PF13_0096               U4/U6.U5 tri-small-nuclear-ribonucleoprotein-associated protein 2   PF10_0041               U5 small nuclear ribonucleoprotein
  PFC0365w                Pre-mRNA-processing factor 19                                       PF10_0041               U5 small nuclear ribonucleoprotein
  PFD0685c                Structural maintenance of chromosomes protein 3                     PF10_0041               U5 small nuclear ribonucleoprotein
  MAL13P1.214             Phosphoethanolamine *N*-methyltransferase                           PFA0455c                Fatty acid elongation protein, GNS1/SUR4 family
  MAL13P1.214             Phosphoethanolamine *N*-methyltransferase                           PFL0950c                Aminophospholipid-transporting P-ATPase
  MAL8P1.17               Protein disulfide isomerase                                         PF10_0092               Metallopeptidase
  MAL8P1.17               Protein disulfide isomerase                                         PFB0920w                DnaJ protein
  PF07_0029               Heat shock protein 86                                               MAL13P1.139             Mitochondrial fission 1 protein
  PF07_0029               Heat shock protein 86                                               PFI0300w                Vacuolar protein sorting-associated protein 46
  PF14_0068               rRNA 2′-*O*-methyltransferase fibrillarin                           PFF1180w                Anaphase-promoting complex subunit
  PF14_0261               Proliferation-associated protein 2g4                                PF14_0612               Zinc finger protein
  PF14_0286               NADP-specific glutamate dehydrogenase                               PF14_0334               NAD(P)H-dependent glutamate synthase
  PF14_0401               tRNA import protein                                                 PF13_0257               Glutamate-tRNA ligase
  PFC0510w                E3 ubiquitin-protein ligase                                         PFI0300w                Vacuolar protein sorting-associated protein 46
  PFE0750c                Pre-mRNA-splicing factor                                            PF14_0688               Pre-mRNA-splicing factor ISY1
  PFF1385c                Conserved Plasmodium protein                                        PFB0920w                DnaJ protein
  PFL1140w                Vacuolar iron transporter                                           PFL0725w                Thioredoxin peroxidase 2

SERCA, sarcoendoplasmic reticulum calcium transport ATPase; ERCC1, excision repair cross-complementation group 1.

The present approach critically depends on the existence of S. cerevisiae genes that (i) possess synthetic lethal phenotypes and (ii) are orthologous to known P. falciparum drug target genes. This seems contradictory; by definition, drug targets are essential and genes with synthetic phenotypes are nonessential. However, we show here that several validated drug targets of P. falciparum possess orthologues in S. cerevisiae that are nonessential ([Table 1](#T1){ref-type="table"}). Phosphoethanolamine methyltransferase and phosphatidylinositol 4-kinase ([Table 1](#T1){ref-type="table"}), for instance, have been demonstrated to be essential enzymes in P. falciparum ([@B24], [@B33]). Most of the genes that are conserved between S. cerevisiae and P. falciparum also have an orthologue in H. sapiens (the OrthoMCL database contains only 80 yeast genes with an orthologue in P. falciparum but not in H. sapiens). We speculate that, of the conserved genes that are essential in yeast, many may also be essential in H. sapiens and their products not suitable as drug targets. On the other hand, conserved genes that are devoid of synthetic phenotypes in yeast might also be disposable in P. falciparum and thus not suitable either. The conserved genes that have synthetic lethal phenotypes in yeast might be the most interesting pharmacologically.

The proposed algorithm strongly narrows the target space for antimalarial drug combinations by including potentially synergistic interactions involving efficacy against P. falciparum as well as toxicity against H. sapiens. The fact that it relies on genome-scale experimental data from S. cerevisiae rather than P. falciparum makes the algorithm straightforward and unbiased but also difficult to validate experimentally. Presently, experimental testing of the identified target pairs in [Table 1](#T1){ref-type="table"} is precluded by the lack of inhibitors for most of the proposed targets. However, we think that the presence of targets such as PfPI4K and PfATP4 in [Table 1](#T1){ref-type="table"} validates the algorithm, and we hope that the algorithm will help identify future combinations of antimalarial molecules that potentiate each other.
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